CA2308639A1 - Methode pour l'utilisation d'inhibiteurs de cyclooxygenase-2 permettant de maintenir le canal arteriel foetal au cours du traitement et de la prevention d'accouchements prematures - Google Patents

Methode pour l'utilisation d'inhibiteurs de cyclooxygenase-2 permettant de maintenir le canal arteriel foetal au cours du traitement et de la prevention d'accouchements prematures Download PDF

Info

Publication number
CA2308639A1
CA2308639A1 CA002308639A CA2308639A CA2308639A1 CA 2308639 A1 CA2308639 A1 CA 2308639A1 CA 002308639 A CA002308639 A CA 002308639A CA 2308639 A CA2308639 A CA 2308639A CA 2308639 A1 CA2308639 A1 CA 2308639A1
Authority
CA
Canada
Prior art keywords
benzenesulfonamide
pyrazol
trifluoromethyl
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002308639A
Other languages
English (en)
Inventor
Philip Needleman
Jaime Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2308639A1 publication Critical patent/CA2308639A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention porte sur l'utilisation d'inhibiteurs de cyclooxygénase-2 ou de dérivés de celle-ci dans la prévention et le traitement du travail préterme. Cette invention porte notamment sur un procédé de prévention et de traitement du travail préterme chez une patiente, ce procédé consistant à traiter la patiente avec une quantité thérapeutiquement efficace d'un composé de la formule (I) dans laquelle R<1>, R<2> et R<3> sont tels que décrits dans la demande.
CA002308639A 1997-10-31 1998-10-27 Methode pour l'utilisation d'inhibiteurs de cyclooxygenase-2 permettant de maintenir le canal arteriel foetal au cours du traitement et de la prevention d'accouchements prematures Abandoned CA2308639A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31
US60/063,889 1997-10-31
PCT/US1998/022246 WO1999022720A2 (fr) 1997-10-31 1998-10-27 Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme

Publications (1)

Publication Number Publication Date
CA2308639A1 true CA2308639A1 (fr) 1999-05-14

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308639A Abandoned CA2308639A1 (fr) 1997-10-31 1998-10-27 Methode pour l'utilisation d'inhibiteurs de cyclooxygenase-2 permettant de maintenir le canal arteriel foetal au cours du traitement et de la prevention d'accouchements prematures

Country Status (9)

Country Link
EP (1) EP1027048A2 (fr)
JP (1) JP2001521889A (fr)
AR (1) AR014000A1 (fr)
AU (1) AU758566B2 (fr)
BR (1) BR9813164A (fr)
CA (1) CA2308639A1 (fr)
TW (2) TW577739B (fr)
WO (1) WO1999022720A2 (fr)
ZA (1) ZA989876B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409123A1 (fr) * 2000-06-08 2001-12-13 The University Of Texas System Derives heterocycliques et techniques d'utilisation
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026731A1 (fr) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. Inhibiteurs de la cyclogenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1997031631A1 (fr) * 1996-02-27 1997-09-04 Rpms Technology Limited Inhibiteurs selectifs de cox-2 destines a la maitrise de la periode de travail et des contractions uterines
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Also Published As

Publication number Publication date
ZA989876B (en) 1999-10-29
TW200404535A (en) 2004-04-01
TW577739B (en) 2004-03-01
EP1027048A2 (fr) 2000-08-16
AR014000A1 (es) 2001-01-31
AU1192699A (en) 1999-05-24
AU758566B2 (en) 2003-03-27
WO1999022720A3 (fr) 1999-08-26
JP2001521889A (ja) 2001-11-13
WO1999022720A2 (fr) 1999-05-14
BR9813164A (pt) 2000-08-22

Similar Documents

Publication Publication Date Title
US6342510B1 (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5990148A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
EP0880362B1 (fr) Compositions renfermant un inhibiteur de cyclooxygenase-2 et un antagoniste de recepteur de leucotriene b 4
US6136839A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
EP0888127B1 (fr) Combinaisons a effets immunodepresseurs renfermant des inhibiteurs de cyclooxygenase-2 et de 5-lipooxygenase
AU745797B2 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US6407140B1 (en) Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU758566B2 (en) Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
EP1400242A1 (fr) Procédé d&#39;utilisation d&#39;inhibiteurs de cyclooxygenase-2 dans le maintien du canal artériel foetal au cours du traitement et de la prévention du travail préterme

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20080618